Gautam Trivedi, MD & CEO of Religare Capital Markets is of the view that one may focus on midcap pharma space.
Gautam Trivedi, MD & CEO of Religare Capital Markets told CNBC-TV18, "The pharma space has been largely misunderstood by the market. It has not been a defensive play, it has been a massive growth play. If you look at the performance of stocks like Sun Pharma and Lupin over the last 10 years, they have been 20-baggers. That phase unlike midcap IT is only just getting started when I look at the midcap stocks within the pharma space whether it is Strides Arcolab, whether it is Shasun Pharma or Natco Pharma – all these stocks are going to be the next Lupin and Sun Pharma within the next 5-10 years."
"So, my view is focus on the midcap pharma space, not so much on the largecap because some of these largecaps are looking expensive but if you have a longer-term view I would buy them anyway."Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.